BRCA1 Pathway Function in Basal-Like Breast Cancer Cells

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Molecular and Cellular Biology

• Publication date

  2014-08-04

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/MCB.01646-13PMID 25092866PMCID PMC4187718
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer

  2015cited by this paper
• Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.

  2013cited by this paper
• Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines

  2013influential reference
• The use of neoadjuvant platinum-based chemotherapy in locally advanced breast cancer that is triple negative: retrospective analysis of 144 patients

  2013cited by this paper
• A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.

  2013cited by this paper
• Molecular insights on basal-like breast cancer

  2012cited by this paper
• Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors.

  2012cited by this paper
• MOLECULAR INSIGHTS ON BASAL-LIKE BREAST CANCER ADVANCES ON BASAL LIKE BREAST CANCER

  2012cited by this paper
• RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1.

  2012cited by this paper
• Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment

  2012cited by this paper
• Links between genome integrity and BRCA1 tumor suppression.

  2012cited by this paper
• BRCA1 exon 11 alternative splicing, multiple functions and the association with cancer.

  2012influential reference
• Mechanisms of BRCA1 tumor suppression.

  2012cited by this paper
• BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair.

  2012cited by this paper
• A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2.

  2012cited by this paper
• BRCA1 is required for postreplication repair after UV-induced DNA damage.

  2011influential reference
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• BRCA1 tumor suppression occurs via heterochromatin mediated silencing

  2011cited by this paper
• Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers

  2011influential reference
• Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience.

  2011cited by this paper
• The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings

  2011cited by this paper
• 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers

  2010cited by this paper
• A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer

  2010cited by this paper
• Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.

  2010cited by this paper
• 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks.

  2010cited by this paper
• BRCA1 and its toolbox for the maintenance of genome integrity

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Phase II studies of gemcitabine and cisplatin in heavily and minimally pretreated metastatic breast cancer.

  2009cited by this paper
• Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies

  2009cited by this paper
• High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.

  2009cited by this paper
• Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase.

  2009influential reference
• Platinum-based chemotherapy in triple-negative breast cancer.

  2008cited by this paper
• Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network

  2008cited by this paper
• Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes.

  2007cited by this paper
• Ten genes for inherited breast cancer.

  2007cited by this paper
• Functional Characterization of a Novel BRCA1-Null Ovarian Cancer Cell Line in Response to Ionizing Radiation

  2007cited by this paper
• BRCA1-IRIS regulates cyclin D1 expression in breast cancer cells.

  2006cited by this paper
• A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.

  2006cited by this paper
• New histone incorporation marks sites of UV repair in human cells.

  2006cited by this paper
• BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.

  2006cited by this paper
• The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly.

  2006cited by this paper
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

  2005cited by this paper
• The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

  2004cited by this paper
• Identification of BRCA1-IRIS, a BRCA1 locus product

  2004cited by this paper
• BRCA1/BARD1 orthologs required for DNA repair in Caenorhabditis elegans.

  2004cited by this paper
• BARD1 Participates with BRCA1 in Homology-Directed Repair of Chromosome Breaks

  2003cited by this paper
• BRCA1-independent ubiquitination of FANCD2.

  2003cited by this paper
• Repeated observation of breast tumor subtypes in independent gene expression data sets

  2003cited by this paper
• The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.

  2002cited by this paper
• Gene expression profiling predicts clinical outcome of breast cancer

  2002cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Local UV‐induced DNA damage in cell nuclei results in local transcription inhibition

  2001cited by this paper
• Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis

  2001cited by this paper
• Sequential assembly of the nucleotide excision repair factors in vivo.

  2001cited by this paper
• Identification of a -Tubulin-binding Domain in BRCA11

  2001cited by this paper
• Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway.

  2001cited by this paper
• Impaired DNA Damage Response in Cells Expressing an Exon 11-Deleted Murine Brca1 Variant That Localizes to Nuclear Foci

  2001cited by this paper
• Identification of a gamma-tubulin-binding domain in BRCA1.

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• The Breast Cancer Susceptibility Gene BRCA1 Is Required for Subnuclear Assembly of Rad51 and Survival following Treatment with the DNA Cross-linking Agent Cisplatin*

  2000cited by this paper
• Genetic analysis of BRCA1 function in a defined tumor cell line.

  1999influential reference
• Brca1 controls homology-directed DNA repair.

  1999influential reference
• XRCC3 promotes homology-directed repair of DNA damage in mammalian cells.

  1999cited by this paper
• Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells.

  1999cited by this paper
• Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells.

  1998cited by this paper
• p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumours

  1998cited by this paper
• Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage.

  1997influential reference
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases

  1997cited by this paper
• Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.

  1997cited by this paper
• Identification of a RING protein that can interact in vivo with the BRCA1 gene product

  1996cited by this paper
• A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.

  1994cited by this paper
• Genomic sequencing.

  1993cited by this paper
• Genomic sequencing.

  1984cited by this paper

• Genetic evidence for PARP1 trapping as a driver of PARP inhibitor efficacy in BRCA mutant cancer cells

  2025cites this paper
• BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine

  2024cites this paper
• The ORFIUS complex regulates ORC2 localization at replication origins

  2024cites this paper
• Protein-Folding Chaperones Predict Structure-Function Relationships and Cancer Risk in BRCA1 Mutation Carriers

  2023cites this paper
• Cationic lipid-conjugated bis-arylidene oxindole derivatives as broad-spectrum breast cancer-selective therapeutics.

  2023cites this paper
• TOP1 inhibition induces bifurcated JNK/MYC signaling that dictates cancer cell sensitivity

  2022cites this paper
• Discovery of druggable cancer-specific pathways with application in acute myeloid leukemia

  2022cites this paper
• Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance

  2022cites this paper
• Exploiting DNA Damage Repair in Precision Cancer Therapy: BRCA1 as a Prime Therapeutic Target

  2021cites this paper
• Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1–AKT–p53 Interactions

  2021cites this paper
• BRCA1/P53: Two strengths in cancer chemoprevention.

  2020cites this paper
• Bioinformatics and Molecular Analysis of the Breast Cancer Susceptibility Gene BRCA1 in Breast Cancer

  2020cites this paper
• CHK1 inhibition exacerbates replication stress induced by IGF blockade

  2020cites this paper
• BRCA1 Mutations in Cancer: Coordinating Deficiencies in Homologous Recombination with Tumorigenesis

  2020cites this paper
• PD-1/PD-L1 axis importance and tumor microenvironment immune cells.

  2020cites this paper
• Enhanced DNA damage response through RAD50 in triple negative breast cancer resistant and cancer stem‐like cells contributes to chemoresistance

  2020cites this paper
• Identification of FUBP1 as a Long Tail Cancer Driver and Widespread Regulator of Tumor Suppressor and Oncogene Alternative Splicing

  2019cites this paper
• BRCA1 Mutation-Specific Responses to 53BP1 Loss-Induced Homologous Recombination and PARP Inhibitor Resistance

  2018cites this paper
• Immunotherapeutic interventions of Triple Negative Breast Cancer

  2018cites this paper
• FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1‐defective cells

  2018cites this paper
• PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer

  2018cites this paper
• Genetic variation in the DNA repair pathway as a potential determinant of response to platinum‐based chemotherapy in breast cancer

  2018cites this paper
• Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells

  2017cites this paper
• NHERF1 together with PARP1 and BRCA1 expression as a new potential biomarker to stratify breast cancer patients

  2017cites this paper
• Predictive biomarkers for triple negative breast cancer treated with platinum-based chemotherapy

  2017cites this paper
• Novel splice‐switching oligonucleotide promotes BRCA1 aberrant splicing and susceptibility to PARP inhibitor action

  2017cites this paper
• Modeling Therapy Resistance in BRCA1/2-Mutant Cancers

  2017cites this paper
• Sensitizing HR-proficient cancers to PARP inhibitors

  2017cites this paper
• Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

  2017cites this paper
• Title BRCA 1 positively regulates FOXO 3 expression by restricting FOXO 3 gene methylation and epigenetic silencing through targeting EZH 2 in breast cancer

  2016cites this paper
• BRCA1-deficient breast cancer cell lines are resistant to MEK inhibitors and show distinct sensitivities to 6-thioguanine

  2016cites this paper
• CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.

  2016influential citation
• Resveratrol Ameliorates Cardiac Hypertrophy by Down‐regulation of miR‐155 Through Activation of Breast Cancer Type 1 Susceptibility Protein

  2016cites this paper
• Predictors and Modulators of Synthetic Lethality: An Update on PARP Inhibitors and Personalized Medicine

  2016influential citation
• BRCA1 positively regulates FOXO3 expression by restricting FOXO3 gene methylation and epigenetic silencing through targeting EZH2 in breast cancer

  2016cites this paper
• Cytotoxic and targeted therapy for hereditary cancers

  2016cites this paper
• University of Dundee BRCA 1 is required for maintenance of phospho-Chk 1 and G 2 / M arrest during DNA cross-link repair in DT 40 cells

  2015cites this paper
• The transcription factor activator protein family of genes in mammary gland development and breast cancer progression

  2015cites this paper
• Clinical performance of diagnostic, prognostic and predictive immunohistochemical biomarkers for hormone receptor-negative breast cancer

  2015cites this paper
• Old drugs, new tricks for triple-negative breast cancer.

  2015cites this paper
• Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?

  2015cites this paper
• The Fanconi Anemia Pathway Protects Genome Integrity from R-loops

  2015cites this paper
• BRCA1 Is Required for Maintenance of Phospho-Chk1 and G2/M Arrest during DNA Cross-Link Repair in DT40 Cells

  2015cites this paper
• SETDB1, HP1 and SUV39 promote repositioning of 53BP1 to extend resection during homologous recombination in G2 cells

  2015cites this paper
• High Levels of Nucleolar Spindle-Associated Protein and Reduced Levels of BRCA1 Expression Predict Poor Prognosis in Triple-Negative Breast Cancer

  2015cites this paper